{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:08:49Z","timestamp":1791828529911,"version":"4.3.4"},"reference-count":149,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T00:00:00Z","timestamp":1605830400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T00:00:00Z","timestamp":1605830400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Gastroenterol Hepatol"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1038\/s41575-020-00378-1","type":"journal-article","created":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T12:16:20Z","timestamp":1605874580000},"page":"181-195","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":114,"title":["Current and emerging therapies for coeliac disease"],"prefix":"10.1038","volume":"18","author":[{"given":"Laura","family":"Kivel\u00e4","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9555-7167","authenticated-orcid":false,"given":"Alberto","family":"Caminero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Leffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9040-9824","authenticated-orcid":false,"given":"Maria Ines","family":"Pinto-Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7687-9654","authenticated-orcid":false,"given":"Jason A.","family":"Tye-Din","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7417-5151","authenticated-orcid":false,"given":"Katri","family":"Lindfors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,20]]},"reference":[{"key":"378_CR1","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.cgh.2017.06.037","volume":"16","author":"P Singh","year":"2018","unstructured":"Singh, P. et al. Global prevalence of celiac disease: systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 16, 823\u2013836.e2 (2018).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"378_CR2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/gutjnl-2011-301346","volume":"62","author":"JF Ludvigsson","year":"2013","unstructured":"Ludvigsson, J. F. et al. The Oslo definitions for coeliac disease and related terms. Gut 62, 43\u201352 (2013).","journal-title":"Gut"},{"key":"378_CR3","doi-asserted-by":"crossref","first-page":"350","DOI":"10.3389\/fped.2018.00350","volume":"6","author":"JA Tye-Din","year":"2018","unstructured":"Tye-Din, J. A., Galipeau, H. J. & Agardh, D. Celiac disease: a review of current concepts in pathogenesis, prevention, and novel therapies. Front. Pediatr. 6, 350 (2018).","journal-title":"Front. Pediatr."},{"key":"378_CR4","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1177\/2050640619844125","volume":"7","author":"A Al-Toma","year":"2019","unstructured":"Al-Toma, A. et al. European society for the study of coeliac disease (ESsCD) guideline for coeliac disease and other gluten-related disorders. United European Gastroenterol. J. 7, 583\u2013613 (2019).","journal-title":"United European Gastroenterol. J."},{"key":"378_CR5","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1053\/j.gastro.2018.12.010","volume":"156","author":"S Husby","year":"2019","unstructured":"Husby, S., Murray, J. A. & Katzka, D. A. AGA clinical practice update on diagnosis and monitoring of celiac disease - changing utility of serology and histologic measures: expert review. Gastroenterology 156, 885\u2013889 (2019).","journal-title":"Gastroenterology"},{"key":"378_CR6","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1136\/flgastro-2019-101191","volume":"11","author":"EMR Baggus","year":"2019","unstructured":"Baggus, E. M. R. et al. How to manage adult coeliac disease: perspective from the NHS England rare diseases collaborative network for non-responsive and refractory coeliac disease. Frontline Gastroenterol. 11, 235\u2013242 (2019).","journal-title":"Frontline Gastroenterol."},{"key":"378_CR7","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1365-2036.2009.04053.x","volume":"30","author":"NJ Hall","year":"2009","unstructured":"Hall, N. J., Rubin, G. & Charnock, A. Systematic review: adherence to a gluten-free diet in adult patients with coeliac disease. Aliment. Pharmacol. Ther. 30, 315\u2013330 (2009).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"378_CR8","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/MPG.0000000000002588","volume":"70","author":"VM Weisbrod","year":"2020","unstructured":"Weisbrod, V. M. et al. A quantitative assessment of gluten cross-contact in the school environment for children with celiac disease. J. Pediatr. Gastroenterol. Nutr. 70, 289\u2013294 (2020).","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"378_CR9","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3390\/nu11020399","volume":"11","author":"A Lee","year":"2019","unstructured":"Lee, A., Wolf, R., Lebwohl, B., Ciaccio, E. & Green, P. Persistent economic burden of the gluten free diet. Nutrients 11, 399 (2019).","journal-title":"Nutrients"},{"key":"378_CR10","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1038\/ajg.2014.29","volume":"109","author":"S Shah","year":"2014","unstructured":"Shah, S. et al. Patient perception of treatment burden is high in celiac disease compared with other common conditions. Am. J. Gastroenterol. 109, 1304\u20131311 (2014).","journal-title":"Am. J. Gastroenterol."},{"key":"378_CR11","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/ygh2.380","volume":"2","author":"AJM Daveson","year":"2020","unstructured":"Daveson, A. J. M. et al. Baseline quantitative histology in therapeutics trials reveals villus atrophy in most patients with coeliac disease who appear well controlled on gluten-free diet. GastroHep 2, 22\u201330 (2020).","journal-title":"GastroHep"},{"key":"378_CR12","doi-asserted-by":"crossref","first-page":"169","DOI":"10.7326\/0003-4819-159-3-201308060-00006","volume":"159","author":"B Lebwohl","year":"2013","unstructured":"Lebwohl, B. et al. Mucosal healing and risk for lymphoproliferative malignancy in celiac disease: a population-based cohort study. Ann. Intern. Med. 159, 169\u2013175 (2013).","journal-title":"Ann. Intern. Med."},{"key":"378_CR13","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1126\/science.1074129","volume":"297","author":"L Shan","year":"2002","unstructured":"Shan, L. et al. Structural basis for gluten intolerance in celiac sprue. Science 297, 2275\u20132279 (2002).","journal-title":"Science"},{"key":"378_CR14","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/nm0797-797","volume":"3","author":"W Dieterich","year":"1997","unstructured":"Dieterich, W. et al. Identification of tissue transglutaminase as the autoantigen of celiac disease. Nat. Med. 3, 797\u2013801 (1997).","journal-title":"Nat. Med."},{"key":"378_CR15","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.3390\/nu11102325","volume":"11","author":"D Cardoso-Silva","year":"2019","unstructured":"Cardoso-Silva, D. et al. Intestinal barrier function in gluten-related disorders. Nutrients 11, 2325 (2019).","journal-title":"Nutrients"},{"key":"378_CR16","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1136\/gutjnl-2015-310148","volume":"66","author":"M Moreno","year":"2017","unstructured":"Moreno, M. et al. Detection of gluten immunogenic peptides in the urine of patients with coeliac disease reveals transgressions in the gluten-free diet and incomplete mucosal healing. Gut 66, 250\u2013257 (2017).","journal-title":"Gut"},{"key":"378_CR17","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.04.018","author":"R Iversen","year":"2020","unstructured":"Iversen, R. et al. Evidence that pathogenic transglutaminase 2 in celiac disease derives from enterocytes. Gastroenterology https:\/\/doi.org\/10.1053\/j.gastro.2020.04.018 (2020).","journal-title":"Gastroenterology"},{"key":"378_CR18","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/nm0698-713","volume":"4","author":"O Molberg","year":"1998","unstructured":"Molberg, O. et al. Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease. Nat. Med. 4, 713\u2013717 (1998).","journal-title":"Nat. Med."},{"key":"378_CR19","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1136\/gutjnl-2016-311713","volume":"65","author":"R Kuja-Halkola","year":"2016","unstructured":"Kuja-Halkola, R. et al. Heritability of non-HLA genetics in coeliac disease: a population-based study in 107 000 twins. Gut 65, 1793\u20131798 (2016).","journal-title":"Gut"},{"key":"378_CR20","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00251-019-01141-w","volume":"72","author":"LM Sollid","year":"2020","unstructured":"Sollid, L. M. et al. Update 2020: nomenclature and listing of celiac disease-relevant gluten epitopes recognized by CD4+ T cells. Immunogenetics 72, 85\u201388 (2020).","journal-title":"Immunogenetics"},{"key":"378_CR21","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1136\/gutjnl-2019-319093","volume":"69","author":"MY Hardy","year":"2020","unstructured":"Hardy, M. Y. et al. Characterisation of clinical and immune reactivity to barley and rye ingestion in children with coeliac disease. Gut 69, 830\u2013840 (2020).","journal-title":"Gut"},{"key":"378_CR22","first-page":"41ra51","volume":"2","author":"JA Tye-Din","year":"2010","unstructured":"Tye-Din, J. A. et al. Comprehensive, quantitative mapping of T cell epitopes in gluten in celiac disease. Sci. Transl Med. 2, 41ra51 (2010).","journal-title":"Sci. Transl Med."},{"key":"378_CR23","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20190860","volume":"217","author":"MF du Pr\u00e9","year":"2020","unstructured":"du Pr\u00e9, M. F. et al. B cell tolerance and antibody production to the celiac disease autoantigen transglutaminase 2. J. Exp. Med. 217, e20190860 (2020).","journal-title":"J. Exp. Med."},{"key":"378_CR24","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1136\/gut.2005.068684","volume":"55","author":"A Di Sabatino","year":"2006","unstructured":"Di Sabatino, A. et al. Epithelium derived interleukin 15 regulates intraepithelial lymphocyte Th1 cytokine production, cytotoxicity, and survival in coeliac disease. Gut 55, 469\u2013477 (2006).","journal-title":"Gut"},{"key":"378_CR25","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/s41586-020-2003-8","volume":"578","author":"V Abadie","year":"2020","unstructured":"Abadie, V. et al. IL-15, gluten and HLA-DQ8 drive tissue destruction in coeliac disease. Nature 578, 600\u2013604 (2020).","journal-title":"Nature"},{"key":"378_CR26","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1126\/science.aah5298","volume":"356","author":"R Bouziat","year":"2017","unstructured":"Bouziat, R. et al. Reovirus infection triggers inflammatory responses to dietary antigens and development of celiac disease. Science 356, 44\u201350 (2017).","journal-title":"Science"},{"key":"378_CR27","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-09037-9","volume":"10","author":"A Caminero","year":"2019","unstructured":"Caminero, A. et al. Duodenal bacterial proteolytic activity determines sensitivity to dietary antigen through protease-activated receptor-2. Nat. Commun. 10, 1198 (2019).","journal-title":"Nat. Commun."},{"key":"378_CR28","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.cgh.2016.10.033","volume":"15","author":"KM Kemppainen","year":"2017","unstructured":"Kemppainen, K. M. et al. Factors that increase risk of celiac disease autoimmunity after a gastrointestinal infection in early life. Clin. Gastroenterol. Hepatol. 15, 694\u2013702.e5 (2017).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"378_CR29","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1136\/gutjnl-2019-319809","volume":"69","author":"K Lindfors","year":"2019","unstructured":"Lindfors, K. et al. Metagenomics of the faecal virome indicate a cumulative effect of enterovirus and gluten amount on the risk of coeliac disease autoimmunity in genetically at risk children: the TEDDY study. Gut 69, 1416\u20131422 (2019).","journal-title":"Gut"},{"key":"378_CR30","doi-asserted-by":"crossref","first-page":"l231","DOI":"10.1136\/bmj.l231","volume":"364","author":"CR Kahrs","year":"2019","unstructured":"Kahrs, C. R. et al. Enterovirus as trigger of coeliac disease: nested case-control study within prospective birth cohort. BMJ 364, l231 (2019).","journal-title":"BMJ"},{"key":"378_CR31","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41575-018-0064-z","volume":"16","author":"A Caminero","year":"2019","unstructured":"Caminero, A., Meisel, M., Jabri, B. & Verdu, E. F. Mechanisms by which gut microorganisms influence food sensitivities. Nat. Rev. Gastroenterol. Hepatol. 16, 7\u201318 (2019).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"378_CR32","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1021\/jf305122s","volume":"61","author":"DD Kasarda","year":"2013","unstructured":"Kasarda, D. D. Can an increase in celiac disease be attributed to an increase in the gluten content of wheat as a consequence of wheat breeding? J. Agric. Food Chem. 61, 1155\u20131159 (2013).","journal-title":"J. Agric. Food Chem."},{"key":"378_CR33","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3390\/nu11030487","volume":"11","author":"M Garc\u00eda-Molina","year":"2019","unstructured":"Garc\u00eda-Molina, M., Gim\u00e9nez, M., S\u00e1nchez-Le\u00f3n, S. & Barro, F. Gluten free wheat: are we there? Nutrients 11, 487 (2019).","journal-title":"Nutrients"},{"key":"378_CR34","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11894-020-0756-8","volume":"22","author":"IA Hujoel","year":"2020","unstructured":"Hujoel, I. A. & Murray, J. A. Refractory celiac disease. Curr. Gastroenterol. Rep. 22, 18 (2020).","journal-title":"Curr. Gastroenterol. Rep."},{"key":"378_CR35","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1053\/j.gastro.2019.12.016","volume":"158","author":"JA Silvester","year":"2019","unstructured":"Silvester, J. A. et al. Most patients with celiac disease on gluten-free diets consume measurable amounts of gluten. Gastroenterology 158, 1497\u20131499.e1 (2019).","journal-title":"Gastroenterology"},{"key":"378_CR36","doi-asserted-by":"crossref","first-page":"792","DOI":"10.14309\/ajg.0000000000000202","volume":"114","author":"BA Lerner","year":"2019","unstructured":"Lerner, B. A. et al. Detection of gluten in gluten-free labeled restaurant food: analysis of crowd-sourced data. Am. J. Gastroenterol. 114, 792\u2013797 (2019).","journal-title":"Am. J. Gastroenterol."},{"key":"378_CR37","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1007\/s10620-018-5285-z","volume":"63","author":"L Viitasalo","year":"2018","unstructured":"Viitasalo, L. et al. Microbial biomarkers in patients with nonresponsive celiac disease. Dig. Dis. Sci. 63, 3434\u20133441 (2018).","journal-title":"Dig. Dis. Sci."},{"key":"378_CR38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jcmgh.2017.01.011","volume":"4","author":"ME Garber","year":"2017","unstructured":"Garber, M. E. et al. A B-cell gene signature correlates with the extent of gluten-induced intestinal injury in celiac disease. Cell. Mol. Gastroenterol. Hepatol. 4, 1\u201317 (2017).","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"378_CR39","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1093\/ajcn\/85.1.160","volume":"85","author":"C Catassi","year":"2007","unstructured":"Catassi, C. et al. A prospective, double-blind, placebo-controlled trial to establish a safe gluten threshold for patients with celiac disease. Am. J. Clin. Nutr. 85, 160\u2013166 (2007).","journal-title":"Am. J. Clin. Nutr."},{"key":"378_CR40","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/1471-230X-11-129","volume":"11","author":"M-L L\u00e4hdeaho","year":"2011","unstructured":"L\u00e4hdeaho, M.-L., M\u00e4ki, M., Laurila, K., Huhtala, H. & Kaukinen, K. Small-bowel mucosal changes and antibody responses after low- and moderate-dose gluten challenge in celiac disease. BMC Gastroenterol. 11, 129 (2011).","journal-title":"BMC Gastroenterol."},{"key":"378_CR41","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1365-277X.2005.00607.x","volume":"18","author":"T Thompson","year":"2005","unstructured":"Thompson, T., Dennis, M., Higgins, L. A., Lee, A. R. & Sharrett, M. K. Gluten-free diet survey: are Americans with coeliac disease consuming recommended amounts of fibre, iron, calcium and grain foods? J. Hum. Nutr. Diet. 18, 163\u2013169 (2005).","journal-title":"J. Hum. Nutr. Diet."},{"key":"378_CR42","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.3390\/nu11071588","volume":"11","author":"G Di Nardo","year":"2019","unstructured":"Di Nardo, G. et al. Nutritional deficiencies in children with celiac disease resulting from a gluten-free diet: a systematic review. Nutrients 11, 1588 (2019).","journal-title":"Nutrients"},{"key":"378_CR43","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.cgh.2017.01.034","volume":"16","author":"SL Raehsler","year":"2018","unstructured":"Raehsler, S. L., Choung, R. S., Marietta, E. V. & Murray, J. A. Accumulation of heavy metals in people on a gluten-free diet. Clin. Gastroenterol. Hepatol. 16, 244\u2013251 (2018).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"378_CR44","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/j.1365-2036.2012.05001.x","volume":"35","author":"TA Kabbani","year":"2012","unstructured":"Kabbani, T. A. et al. Body mass index and the risk of obesity in coeliac disease treated with the gluten-free diet. Aliment. Pharmacol. Ther. 35, 723\u2013729 (2012).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"378_CR45","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1365-277X.2011.01160.x","volume":"24","author":"J Singh","year":"2011","unstructured":"Singh, J. & Whelan, K. Limited availability and higher cost of gluten-free foods. J. Hum. Nutr. Diet. 24, 479\u2013486 (2011).","journal-title":"J. Hum. Nutr. Diet."},{"key":"378_CR46","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2016-4367","volume":"139","author":"K M\u00e5rild","year":"2017","unstructured":"M\u00e5rild, K. et al. Celiac disease and anorexia nervosa: a nationwide study. Pediatrics 139, e20164367 (2017).","journal-title":"Pediatrics"},{"key":"378_CR47","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/jhn.12316","volume":"29","author":"JA Silvester","year":"2016","unstructured":"Silvester, J. A., Weiten, D., Graff, L. A., Walker, J. R. & Duerksen, D. R. Living gluten-free: adherence, knowledge, lifestyle adaptations and feelings towards a gluten-free diet. J. Hum. Nutr. Diet. 29, 374\u2013382 (2016).","journal-title":"J. Hum. Nutr. Diet."},{"key":"378_CR48","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1177\/2050640614560786","volume":"3","author":"F Zingone","year":"2015","unstructured":"Zingone, F. et al. Psychological morbidity of celiac disease: a review of the literature. U Eur. Gastroenterol. J. 3, 136\u2013145 (2015).","journal-title":"U Eur. Gastroenterol. J."},{"key":"378_CR49","volume":"7","author":"J K\u00f6nig","year":"2017","unstructured":"K\u00f6nig, J., Holster, S., Bruins, M. J. & Brummer, R. J. Randomized clinical trial: Effective gluten degradation by Aspergillus niger-derived enzyme in a complex meal setting. Sci. Rep. 7, 13100 (2017).","journal-title":"Sci. Rep."},{"key":"378_CR50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0017366","volume":"6","author":"AJ Daveson","year":"2011","unstructured":"Daveson, A. J. et al. Effect of hookworm infection on wheat challenge in celiac disease\u2013a randomised double-blinded placebo controlled trial. PLoS ONE 6, e17366 (2011).","journal-title":"PLoS ONE"},{"key":"378_CR51","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1016\/j.jid.2019.03.1150","volume":"139","author":"E Mansikkka","year":"2019","unstructured":"Mansikkka, E. et al. Gluten challenge induces skin and small-bowel relapse in long-term gluten-free diet -treated dermatitis herpetiformis. J. Invest. Dermatol. 139, 2108\u20132114 (2019).","journal-title":"J. Invest. Dermatol."},{"key":"378_CR52","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/apt.15551","volume":"51","author":"AJM Daveson","year":"2020","unstructured":"Daveson, A. J. M. et al. Masked bolus gluten challenge low in FODMAPs implicates nausea and vomiting as key symptoms associated with immune activation in treated coeliac disease. Aliment. Pharmacol. Ther. 51, 244\u2013252 (2020).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"378_CR53","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1136\/gutjnl-2017-314853","volume":"67","author":"JF Ludvigsson","year":"2018","unstructured":"Ludvigsson, J. F. et al. Outcome measures in coeliac disease trials: the Tampere recommendations. Gut 67, 1410\u20131424 (2018).","journal-title":"Gut"},{"key":"378_CR54","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jclinepi.2013.08.015","volume":"67","author":"J McCambridge","year":"2014","unstructured":"McCambridge, J., Witton, J. & Elbourne, D. R. Systematic review of the Hawthorne effect: New concepts are needed to study research participation effects. J. Clin. Epidemiol. 67, 267\u2013277 (2014).","journal-title":"J. Clin. Epidemiol."},{"key":"378_CR55","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.peptides.2012.02.015","volume":"35","author":"S Gopalakrishnan","year":"2012","unstructured":"Gopalakrishnan, S. et al. Larazotide acetate regulates epithelial tight junctions in vitro and in vivo. Peptides 35, 86\u201394 (2012).","journal-title":"Peptides"},{"key":"378_CR56","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/j.1365-2036.2007.03413.x","volume":"26","author":"BM Paterson","year":"2007","unstructured":"Paterson, B. M., Lammers, K. M., Arrieta, M. C., Fasano, A. & Meddings, J. B. The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study. Aliment. Pharmacol. Ther. 26, 757\u2013766 (2007).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"378_CR57","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1038\/ajg.2012.211","volume":"107","author":"DA Leffler","year":"2012","unstructured":"Leffler, D. A. et al. A randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during gluten challenge. Am. J. Gastroenterol. 107, 1554\u20131562 (2012).","journal-title":"Am. J. Gastroenterol."},{"key":"378_CR58","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/apt.12147","volume":"37","author":"CP Kelly","year":"2013","unstructured":"Kelly, C. P. et al. Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study. Aliment. Pharmacol. Ther. 37, 252\u2013262 (2013).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"378_CR59","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1053\/j.gastro.2015.02.008","volume":"148","author":"DA Leffler","year":"2015","unstructured":"Leffler, D. A. et al. Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial. Gastroenterology 148, 1311\u20139.e6 (2015).","journal-title":"Gastroenterology"},{"key":"378_CR60","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03569007 (2019)."},{"key":"378_CR61","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00620451 (2017)."},{"key":"378_CR62","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-48299-7","volume":"9","author":"L Cavaletti","year":"2019","unstructured":"Cavaletti, L. et al. E40, a novel microbial protease efficiently detoxifying gluten proteins, for the dietary management of gluten intolerance. Sci. Rep. 9, 13147 (2019).","journal-title":"Sci. Rep."},{"key":"378_CR63","volume":"6","author":"M Rey","year":"2016","unstructured":"Rey, M. et al. Addressing proteolytic efficiency in enzymatic degradation therapy for celiac disease. Sci. Rep. 6, 30980 (2016).","journal-title":"Sci. Rep."},{"key":"378_CR64","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.clim.2009.11.001","volume":"134","author":"JA Tye-Din","year":"2010","unstructured":"Tye-Din, J. A. et al. The effects of ALV003 pre-digestion of gluten on immune response and symptoms in celiac disease in vivo. Clin. Immunol. 134, 289\u2013295 (2010).","journal-title":"Clin. Immunol."},{"key":"378_CR65","doi-asserted-by":"crossref","first-page":"13106","DOI":"10.1021\/jacs.5b08325","volume":"137","author":"C Wolf","year":"2015","unstructured":"Wolf, C. et al. Engineering of Kuma030: a gliadin peptidase that rapidly degrades immunogenic gliadin peptides in gastric conditions. J. Am. Chem. Soc. 137, 13106\u201313113 (2015).","journal-title":"J. Am. Chem. Soc."},{"key":"378_CR66","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/B978-0-12-416039-2.00013-6","volume":"502","author":"MT Bethune","year":"2012","unstructured":"Bethune, M. T. & Khosla, C. Oral enzyme therapy for celiac sprue. Methods Enzymol. 502, 241\u2013271 (2012).","journal-title":"Methods Enzymol."},{"key":"378_CR67","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/gut.2006.111609","volume":"57","author":"C Mitea","year":"2008","unstructured":"Mitea, C. et al. Efficient degradation of gluten by a prolyl endoprotease in a gastrointestinal model: implications for coeliac disease. Gut 57, 25\u201332 (2008).","journal-title":"Gut"},{"key":"378_CR68","doi-asserted-by":"crossref","first-page":"5837","DOI":"10.3748\/wjg.v19.i35.5837","volume":"19","author":"GJ Tack","year":"2013","unstructured":"Tack, G. J. et al. Consumption of gluten with gluten-degrading enzyme by celiac patients: a pilot-study. World J. Gastroenterol. 19, 5837\u20135847 (2013).","journal-title":"World J. Gastroenterol."},{"key":"378_CR69","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/apt.13266","volume":"42","author":"BN Salden","year":"2015","unstructured":"Salden, B. N. et al. Randomised clinical study: Aspergillus niger-derived enzyme digests gluten in the stomach of healthy volunteers. Aliment. Pharmacol. Ther. 42, 273\u2013285 (2015).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"378_CR70","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00810654 (2011)."},{"key":"378_CR71","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0006313","volume":"4","author":"J Ehren","year":"2009","unstructured":"Ehren, J. et al. A food-grade enzyme preparation with modest gluten detoxification properties. PLoS ONE 4, e6313 (2009).","journal-title":"PLoS ONE"},{"key":"378_CR72","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00962182 (2018)."},{"key":"378_CR73","first-page":"E68","volume":"50","author":"IR Korponay-Szab\u00f3","year":"2010","unstructured":"Korponay-Szab\u00f3, I. R. et al. Food-grade gluten degrading enzymes to treat dietary transgressions in coeliac adolescents. J. Pediatr. Gastroenterol. Nutr. 50, E68 (2010).","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"378_CR74","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1053\/j.gastro.2007.05.028","volume":"133","author":"J Gass","year":"2007","unstructured":"Gass, J., Bethune, M. T., Siegel, M., Spencer, A. & Khosla, C. Combination enzyme therapy for gastric digestion of dietary gluten in patients with celiac sprue. Gastroenterology 133, 472\u2013480 (2007).","journal-title":"Gastroenterology"},{"key":"378_CR75","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1007\/s10620-011-1906-5","volume":"57","author":"M Siegel","year":"2012","unstructured":"Siegel, M. et al. Safety, tolerability, and activity of ALV003: results from two phase 1 single, escalating-dose clinical trials. Dig. Dis. Sci. 57, 440\u2013450 (2012).","journal-title":"Dig. Dis. Sci."},{"key":"378_CR76","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1053\/j.gastro.2014.02.031","volume":"146","author":"M-L L\u00e4hdeaho","year":"2014","unstructured":"L\u00e4hdeaho, M.-L. et al. Glutenase ALV003 attenuates gluten-induced mucosal injury in patients with celiac disease. Gastroenterology 146, 1649\u20131658 (2014).","journal-title":"Gastroenterology"},{"key":"378_CR77","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1053\/j.gastro.2016.11.004","volume":"152","author":"J Murray","year":"2017","unstructured":"Murray, J. et al. No difference between latiglutenase and placebo in reducing villous atrophy or improving symptoms in patients with symptomatic celiac disease. Gastroenterology 152, 787\u2013798.e2 (2017).","journal-title":"Gastroenterology"},{"key":"378_CR78","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1007\/s10620-017-4687-7","volume":"62","author":"JA Syage","year":"2017","unstructured":"Syage, J. A., Murray, J. A., Green, P. H. R. & Khosla, C. Latiglutenase improves symptoms in seropositive celiac disease patients while on a gluten-free diet. Dig. Dis. Sci. 62, 2428\u20132432 (2017).","journal-title":"Dig. Dis. Sci."},{"key":"378_CR79","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03585478 (2019)."},{"key":"378_CR80","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04243551 (2020)."},{"key":"378_CR81","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S2468-1253(19)30264-X","volume":"4","author":"M-L L\u00e4hdeaho","year":"2019","unstructured":"L\u00e4hdeaho, M.-L. et al. Safety and efficacy of AMG 714 in adults with coeliac disease exposed to gluten challenge: a phase 2a, randomised, double-blind, placebo-controlled study. Lancet Gastroenterol. Hepatol. 4, 948\u2013959 (2019).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"378_CR82","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/S2468-1253(19)30265-1","volume":"4","author":"C Cellier","year":"2019","unstructured":"Cellier, C. et al. Safety and efficacy of AMG 714 in patients with type 2 refractory coeliac disease: a phase 2a, randomised, double-blind, placebo-controlled, parallel-group study. Lancet Gastroenterol. Hepatol. 4, 960\u2013970 (2019).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"378_CR83","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04424927 (2020)."},{"key":"378_CR84","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1038\/jidsymp.2013.8","volume":"16","author":"TA Waldmann","year":"2013","unstructured":"Waldmann, T. A. The biology of IL-15: implications for cancer therapy and the treatment of autoimmune disorders. J. Investig. Dermatol. Symp. Proc. 16, S28\u2013S30 (2013).","journal-title":"J. Investig. Dermatol. Symp. Proc."},{"key":"378_CR85","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1053\/j.gastro.2019.10.006","volume":"158","author":"C Ciszewski","year":"2020","unstructured":"Ciszewski, C. et al. Identification of a \u03b3c receptor antagonist that prevents reprogramming of human tissue-resident cytotoxic t cells by IL15 and IL21. Gastroenterology 158, 625\u2013637.e13 (2020).","journal-title":"Gastroenterology"},{"key":"378_CR86","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01893775 (2020)."},{"key":"378_CR87","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/s10875-012-9849-y","volume":"33","author":"S Yokoyama","year":"2013","unstructured":"Yokoyama, S., Perera, P.-Y., Waldmann, T. A., Hiroi, T. & Perera, L. P. Tofacitinib, a janus kinase inhibitor demonstrates efficacy in an IL-15 transgenic mouse model that recapitulates pathologic manifestations of celiac disease. J. Clin. Immunol. 33, 586\u2013594 (2013).","journal-title":"J. Clin. Immunol."},{"key":"378_CR88","unstructured":"EU Clinical Trials Register. ClinicalTrialsRegister.eu https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=2018-001678-10 (2018)."},{"key":"378_CR89","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00540657 (2008)."},{"key":"378_CR90","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04524221 (2020)."},{"key":"378_CR91","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-01894-y","volume":"7","author":"M Tato","year":"2017","unstructured":"Tato, M. et al. Cathepsin S inhibition combines control of systemic and peripheral pathomechanisms of autoimmune tissue injury. Sci. Rep. 7, 2775 (2017).","journal-title":"Sci. Rep."},{"key":"378_CR92","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02679014 (2017)."},{"key":"378_CR93","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jaut.2007.11.007","volume":"30","author":"M Abraham","year":"2008","unstructured":"Abraham, M. et al. In vitro induction of regulatory T cells by anti-CD3 antibody in humans. J. Autoimmun. 30, 21\u201328 (2008).","journal-title":"J. Autoimmun."},{"key":"378_CR94","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3390\/antib8020032","volume":"8","author":"LS H\u00f8ydahl","year":"2019","unstructured":"H\u00f8ydahl, L. S., Frick, R., Sandlie, I. & L\u00f8set, G. \u00c5. Targeting the MHC ligandome by use of TCR-like antibodies. Antibodies 8, 32 (2019).","journal-title":"Antibodies"},{"key":"378_CR95","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1084\/jem.20182287","volume":"216","author":"JM Carballido","year":"2019","unstructured":"Carballido, J. M. & Santamaria, P. Taming autoimmunity: Translating antigen-specific approaches to induce immune tolerance. J. Exp. Med. 216, 247\u2013250 (2019).","journal-title":"J. Exp. Med."},{"key":"378_CR96","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.molmed.2019.05.009","volume":"25","author":"A Christophersen","year":"2019","unstructured":"Christophersen, A., Risnes, L. F., Dahal-Koirala, S. & Sollid, L. M. Therapeutic and diagnostic implications of t cell scarring in celiac disease and beyond. Trends Mol. Med. 25, 836\u2013852 (2019).","journal-title":"Trends Mol. Med."},{"key":"378_CR97","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1172\/JCI98819","volume":"128","author":"LF Risnes","year":"2018","unstructured":"Risnes, L. F. et al. Disease-driving CD4+ T cell clonotypes persist for decades in celiac disease. J. Clin. Invest. 128, 2642\u20132650 (2018).","journal-title":"J. Clin. Invest."},{"key":"378_CR98","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S2468-1253(17)30110-3","volume":"2","author":"G Goel","year":"2017","unstructured":"Goel, G. et al. Epitope-specific immunotherapy targeting CD4-positive T cells in coeliac disease: two randomised, double-blind, placebo-controlled phase 1 studies. Lancet. Gastroenterol. Hepatol. 2, 479\u2013493 (2017).","journal-title":"Lancet. Gastroenterol. Hepatol."},{"key":"378_CR99","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ebiom.2017.11.018","volume":"26","author":"AJM Daveson","year":"2017","unstructured":"Daveson, A. J. M. et al. Epitope-specific immunotherapy targeting CD4-positive T cells in celiac disease: safety, pharmacokinetics, and effects on intestinal histology and plasma cytokines with escalating dose regimens of Nexvax2 in a Randomized, double-blind, placebo-controlled. EBioMedicine 26, 78\u201390 (2017).","journal-title":"EBioMedicine"},{"key":"378_CR100","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aaw7756","volume":"5","author":"G Goel","year":"2019","unstructured":"Goel, G. et al. Cytokine release and gastrointestinal symptoms after gluten challenge in celiac disease. Sci. Adv. 5, eaaw7756 (2019).","journal-title":"Sci. Adv."},{"key":"378_CR101","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03644069 (2019)."},{"key":"378_CR102","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/apt.15494","volume":"50","author":"KE Truitt","year":"2019","unstructured":"Truitt, K. E. & Anderson, R. P. Editorial: a non-dietary treatment for coeliac disease-two steps forward, one step back? Authors\u2019 reply. Aliment. Pharmacol. Ther. 50, 956\u2013957 (2019).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"378_CR103","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1053\/j.gastro.2020.01.045","volume":"158","author":"TL Freitag","year":"2020","unstructured":"Freitag, T. L. et al. Gliadin nanoparticles induce immune tolerance to gliadin in mouse models of celiac disease. Gastroenterology 158, 1667\u20131681.e12 (2020).","journal-title":"Gastroenterology"},{"key":"378_CR104","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03486990 (2020)."},{"key":"378_CR105","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03738475 (2020)."},{"key":"378_CR106","first-page":"1421","volume":"7","author":"C Kelly","year":"2019","unstructured":"Kelly, C. et al. CNP-101 prevents gluten challenge-induced immune activation in adults with celiac disease [abstract]. United Eur. Gastroenterol. J. 7, 1421 (2019).","journal-title":"United Eur. Gastroenterol. J."},{"key":"378_CR107","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04530123 (2020)."},{"key":"378_CR108","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/nature16962","volume":"530","author":"X Clemente-Casares","year":"2016","unstructured":"Clemente-Casares, X. et al. Expanding antigen-specific regulatory networks to treat autoimmunity. Nature 530, 434\u2013440 (2016).","journal-title":"Nature"},{"key":"378_CR109","doi-asserted-by":"crossref","DOI":"10.1038\/srep15907","volume":"5","author":"AJ Grimm","year":"2015","unstructured":"Grimm, A. J., Kontos, S., Diaceri, G., Quaglia-Thermes, X. & Hubbell, J. A. Memory of tolerance and induction of regulatory T cells by erythrocyte-targeted antigens. Sci. Rep. 5, 15907 (2015).","journal-title":"Sci. Rep."},{"key":"378_CR110","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04248855 (2020)."},{"key":"378_CR111","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/MOG.0b013e3283572f73","volume":"28","author":"DE Elliot","year":"2012","unstructured":"Elliot, D. E. & Weinstock, J. V. Where are we on worms? Curr. Opin. Gastroenterol. 28, 551\u2013556 (2012).","journal-title":"Curr. Opin. Gastroenterol."},{"key":"378_CR112","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.jaci.2014.07.022","volume":"135","author":"J Croese","year":"2015","unstructured":"Croese, J. et al. Experimental hookworm infection and gluten microchallenge promote tolerance in celiac disease. J. Allergy Clin. Immunol. 135, 508\u2013516 (2015).","journal-title":"J. Allergy Clin. Immunol."},{"key":"378_CR113","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02754609 (2020)."},{"key":"378_CR114","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1517\/14728222.2014.985207","volume":"19","author":"A-M Sulic","year":"2015","unstructured":"Sulic, A.-M., Kurppa, K., Rauhavirta, T., Kaukinen, K. & Lindfors, K. Transglutaminase as a therapeutic target for celiac disease. Expert Opin. Ther. Targets 19, 335\u2013348 (2015).","journal-title":"Expert Opin. Ther. Targets"},{"key":"378_CR115","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1002\/pro.2162","volume":"21","author":"C Kl\u00f6ck","year":"2012","unstructured":"Kl\u00f6ck, C. & Khosla, C. Regulation of the activities of the mammalian transglutaminase family of enzymes. Protein Sci. 21, 1781\u20131791 (2012).","journal-title":"Protein Sci."},{"key":"378_CR116","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/1521-4141(200105)31:5<1317::AID-IMMU1317>3.0.CO;2-I","volume":"31","author":"\u00d8 Molberg","year":"2001","unstructured":"Molberg, \u00d8. et al. T cells from celiac disease lesions recognize gliadin epitopes deamidated in situ by endogenous tissue transglutaminase. Eur. J. Immunol. 31, 1317\u20131323 (2001).","journal-title":"Eur. J. Immunol."},{"key":"378_CR117","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1053\/j.gastro.2005.07.054","volume":"129","author":"L Maiuri","year":"2005","unstructured":"Maiuri, L. et al. Unexpected role of surface transglutaminase type II in celiac disease. Gastroenterology 129, 1400\u20131413 (2005).","journal-title":"Gastroenterology"},{"key":"378_CR118","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1365-2249.2010.04317.x","volume":"164","author":"T Rauhavirta","year":"2011","unstructured":"Rauhavirta, T. et al. Epithelial transport and deamidation of gliadin peptides: a role for coeliac disease patient immunoglobulin A. Clin. Exp. Immunol. 164, 127\u2013136 (2011).","journal-title":"Clin. Exp. Immunol."},{"key":"378_CR119","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1053\/j.gastro.2012.05.051","volume":"143","author":"C Lebreton","year":"2012","unstructured":"Lebreton, C. et al. Interactions among secretory immunoglobulin A, CD71, and transglutaminase-2 affect permeability of intestinal epithelial cells to gliadin peptides. Gastroenterology 143, 698\u2013707.e4 (2012).","journal-title":"Gastroenterology"},{"key":"378_CR120","doi-asserted-by":"crossref","first-page":"S-490","DOI":"10.1016\/S0016-5085(18)31861-4","volume":"154","author":"MAE Ventura","year":"2018","unstructured":"Ventura, M. A. E. et al. Su1161 - The oral transglutaminase 2 (TG2) inhibitor Zed1227 blocks TG2 activity in a mouse model of intestinal inflammation [Abstract]. Gastroenterology 154, S-490 (2018).","journal-title":"Gastroenterology"},{"key":"378_CR121","unstructured":"EU Clinical Trials Register. ClinicalTrialsRegister.eu https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=2017-002241-30 (2017)."},{"key":"378_CR122","doi-asserted-by":"crossref","first-page":"25402","DOI":"10.1074\/jbc.M109.097162","volume":"285","author":"J Stamnaes","year":"2010","unstructured":"Stamnaes, J., Pinkas, D. M., Fleckenstein, B., Khosla, C. & Sollid, L. M. Redox regulation of transglutaminase 2 activity. J. Biol. Chem. 285, 25402\u201325409 (2010).","journal-title":"J. Biol. Chem."},{"key":"378_CR123","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1021\/acs.biochem.8b00204","volume":"57","author":"BA Palanski","year":"2018","unstructured":"Palanski, B. A. & Khosla, C. Cystamine and disulfiram inhibit human transglutaminase 2 via an oxidative mechanism. Biochemistry 57, 3359\u20133363 (2018).","journal-title":"Biochemistry"},{"key":"378_CR124","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1021\/jf205319s","volume":"60","author":"N Gujral","year":"2012","unstructured":"Gujral, N., L\u00f6benberg, R., Suresh, M. & Sunwoo, H. In-vitro and in-vivo binding activity of chicken egg yolk immunoglobulin Y (IgY) against gliadin in food matrix. J. Agric. Food Chem. 60, 3166\u20133172 (2012).","journal-title":"J. Agric. Food Chem."},{"key":"378_CR125","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1007\/s10620-016-4426-5","volume":"62","author":"DA Sample","year":"2017","unstructured":"Sample, D. A. et al. AGY, a novel egg yolk-derived anti-gliadin antibody, is safe for patients with celiac disease. Dig. Dis. Sci. 62, 1277\u20131285 (2017).","journal-title":"Dig. Dis. Sci."},{"key":"378_CR126","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03707730 (2019)."},{"key":"378_CR127","doi-asserted-by":"crossref","DOI":"10.1186\/s12896-015-0223-z","volume":"15","author":"V Stadlmann","year":"2015","unstructured":"Stadlmann, V. et al. Novel avian single-chain fragment variable (scFv) targets dietary gluten and related natural grain prolamins, toxic entities of celiac disease. BMC Biotechnol. 15, 109 (2015).","journal-title":"BMC Biotechnol."},{"key":"378_CR128","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/bip.21109","volume":"91","author":"L Liang","year":"2009","unstructured":"Liang, L., Pinier, M., Leroux, J.-C. & Subirade, M. Interaction of alpha-gliadin with poly(HEMA-co-SS): structural characterization and biological implication. Biopolymers 91, 169\u2013178 (2009).","journal-title":"Biopolymers"},{"key":"378_CR129","volume":"9","author":"JL McCarville","year":"2014","unstructured":"McCarville, J. L. et al. BL-7010 demonstrates specific binding to gliadin and reduces gluten-associated pathology in a chronic mouse model of gliadin sensitivity. PLoS ONE 9, e109972 (2014).","journal-title":"PLoS ONE"},{"key":"378_CR130","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01990885 (2017)."},{"key":"378_CR131","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1053\/j.gastro.2016.06.041","volume":"151","author":"A Caminero","year":"2016","unstructured":"Caminero, A. et al. Duodenal bacteria from patients with celiac disease and healthy subjects distinctly affect gluten breakdown and immunogenicity. Gastroenterology 151, 670\u2013683 (2016).","journal-title":"Gastroenterology"},{"key":"378_CR132","doi-asserted-by":"crossref","first-page":"988","DOI":"10.3390\/nu10080988","volume":"10","author":"K Hiippala","year":"2018","unstructured":"Hiippala, K. et al. The potential of gut commensals in reinforcing intestinal barrier function and alleviating inflammation. Nutrients 10, 988 (2018).","journal-title":"Nutrients"},{"key":"378_CR133","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1038\/s41591-019-0461-z","volume":"25","author":"A Abdel-Gadir","year":"2019","unstructured":"Abdel-Gadir, A. et al. Microbiota therapy acts via a regulatory T cell MyD88\/ROR\u03b3t pathway to suppress food allergy. Nat. Med. 25, 1164\u20131174 (2019).","journal-title":"Nat. Med."},{"key":"378_CR134","doi-asserted-by":"crossref","first-page":"e01323","DOI":"10.1128\/AEM.01323-17","volume":"83","author":"JL McCarville","year":"2017","unstructured":"McCarville, J. L. et al. A commensal Bifidobacterium longum strain prevents gluten-related immunopathology in mice through expression of a serine protease inhibitor. Appl. Environ. Microbiol. 83, e01323\u201317 (2017).","journal-title":"Appl. Environ. Microbiol."},{"key":"378_CR135","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/labinvest.2012.13","volume":"92","author":"C Papista","year":"2012","unstructured":"Papista, C. et al. Gluten induces coeliac-like disease in sensitised mice involving IgA, CD71 and transglutaminase 2 interactions that are prevented by probiotics. Lab. Invest. 92, 625\u2013635 (2012).","journal-title":"Lab. Invest."},{"key":"378_CR136","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.4049\/jimmunol.0802891","volume":"183","author":"IL Huibregtse","year":"2009","unstructured":"Huibregtse, I. L. et al. Induction of antigen-specific tolerance by oral administration of Lactococcus lactis delivered immunodominant DQ8-restricted gliadin peptide in sensitized nonobese diabetic Abo Dq8 transgenic mice. J. Immunol. 183, 2390\u20132396 (2009).","journal-title":"J. Immunol."},{"key":"378_CR137","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1017\/S0007114514000609","volume":"112","author":"M Olivares","year":"2014","unstructured":"Olivares, M., Castillejo, G., Varea, V. & Sanz, Y. Double-blind, randomised, placebo-controlled intervention trial to evaluate the effects of Bifidobacterium longum CECT 7347 in children with newly diagnosed coeliac disease. Br. J. Nutr. 112, 30\u201340 (2014).","journal-title":"Br. J. Nutr."},{"key":"378_CR138","doi-asserted-by":"crossref","first-page":"660","DOI":"10.3390\/nu8100660","volume":"8","author":"A Quagliariello","year":"2016","unstructured":"Quagliariello, A. et al. Effect of Bifidobacterium breve on the intestinal microbiota of coeliac children on a gluten free diet: a pilot study. Nutrients 8, 660 (2016).","journal-title":"Nutrients"},{"key":"378_CR139","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1007\/s10620-015-3769-7","volume":"60","author":"M Klemenak","year":"2015","unstructured":"Klemenak, M., Dolin\u0161ek, J., Langerholc, T., Di Gioia, D. & Mi\u010deti\u0107-Turk, D. Administration of Bifidobacterium breve Decreases the production of TNF-\u03b1 in children with celiac disease. Dig. Dis. Sci. 60, 3386\u20133392 (2015).","journal-title":"Dig. Dis. Sci."},{"key":"378_CR140","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.clnu.2018.06.931","volume":"38","author":"M Primec","year":"2019","unstructured":"Primec, M. et al. Clinical intervention using Bifidobacterium strains in celiac disease children reveals novel microbial modulators of TNF-\u03b1 and short-chain fatty acids. Clin. Nutr. 38, 1373\u20131381 (2019).","journal-title":"Clin. Nutr."},{"key":"378_CR141","doi-asserted-by":"crossref","first-page":"9048574","DOI":"10.1155\/2016\/9048574","volume":"2016","author":"J Harnett","year":"2016","unstructured":"Harnett, J., Myers, S. P. & Rolfe, M. Probiotics and the microbiome in celiac disease: a randomised controlled trial. Evid. Based Complement. Alternat. Med. 2016, 9048574 (2016).","journal-title":"Evid. Based Complement. Alternat. Med."},{"key":"378_CR142","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1097\/MCG.0000000000001023","volume":"53","author":"R Francavilla","year":"2019","unstructured":"Francavilla, R. et al. Clinical and microbiological effect of a multispecies probiotic supplementation in celiac patients with persistent IBS-type symptoms: a randomized, double-blind, placebo-controlled, multicenter trial. J. Clin. Gastroenterol. 53, e117\u2013e125 (2019).","journal-title":"J. Clin. Gastroenterol."},{"key":"378_CR143","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/MCG.0b013e31827759ac","volume":"47","author":"E Smecuol","year":"2013","unstructured":"Smecuol, E. et al. Exploratory, randomized, double-blind, placebo-controlled study on the effects of Bifidobacterium infantis natren life start strain super strain in active celiac disease. J. Clin. Gastroenterol. 47, 139\u2013147 (2013).","journal-title":"J. Clin. Gastroenterol."},{"key":"378_CR144","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1097\/MCG.0000000000000687","volume":"51","author":"MI Pinto-S\u00e1nchez","year":"2017","unstructured":"Pinto-S\u00e1nchez, M. I. et al. Bifidobacterium infantis NLS super strain reduces the expression of \u03b1-defensin-5, a marker of innate immunity, in the mucosa of active celiac disease patients. J. Clin. Gastroenterol. 51, 814\u2013817 (2017).","journal-title":"J. Clin. Gastroenterol."},{"key":"378_CR145","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1056\/NEJMoa1404172","volume":"371","author":"SL Vriezinga","year":"2014","unstructured":"Vriezinga, S. L. et al. Randomized feeding intervention in infants at high risk for celiac disease. N. Engl. J. Med. 371, 1304\u20131315 (2014).","journal-title":"N. Engl. J. Med."},{"key":"378_CR146","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1056\/NEJMoa1400697","volume":"371","author":"E Lionetti","year":"2014","unstructured":"Lionetti, E. et al. Introduction of gluten, HLA status, and the risk of celiac disease in children. N. Engl. J. Med. 371, 1295\u20131303 (2014).","journal-title":"N. Engl. J. Med."},{"key":"378_CR147","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.3390\/nu11081925","volume":"11","author":"\u00c5 H\u00e5kansson","year":"2019","unstructured":"H\u00e5kansson, \u00c5. et al. Effects of Lactobacillus plantarum and Lactobacillus paracasei on the peripheral immune response in children with celiac disease autoimmunity: a randomized, double-blind, placebo-controlled clinical trial. Nutrients 11, 1925 (2019).","journal-title":"Nutrients"},{"key":"378_CR148","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.3390\/nu11081790","volume":"11","author":"U Uusitalo","year":"2019","unstructured":"Uusitalo, U. et al. Early probiotic supplementation and the risk of celiac disease in children at genetic risk. Nutrients 11, 1790 (2019).","journal-title":"Nutrients"},{"key":"378_CR149","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03562221 (2020)."}],"container-title":["Nature Reviews Gastroenterology &amp; Hepatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41575-020-00378-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41575-020-00378-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41575-020-00378-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:52:21Z","timestamp":1684605141000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41575-020-00378-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,20]]},"references-count":149,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["378"],"URL":"https:\/\/doi.org\/10.1038\/s41575-020-00378-1","relation":{},"ISSN":["1759-5045","1759-5053"],"issn-type":[{"value":"1759-5045","type":"print"},{"value":"1759-5053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,20]]},"assertion":[{"value":"19 October 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L.K. reports personal fees for lectures from the Finnish Coeliac Society outside the submitted work and participation in the AMG 714 trial. D.A.L. is the Medical Director for Takeda Pharmaceuticals. J.T.-D. is an inventor of patents pertaining to the use of gluten-derived T cell epitopes for use in coeliac disease therapeutics and was an investigator in the Nexvax2 phase II trial. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}